Summary of clinical trials with zafirlukast - Wikidata - wikimedia - TriplyDB

Summary of clinical trials with zafirlukast

Summary of clinical trials with zafirlukast

http://www.wikidata.org/entity/Q42541808

about

The effects of zafirlukast on capsular contracture: preliminary report Pharmacotherapy of asthma in children, with special reference to leukotriene receptor antagonists.Comparative protection against rat intestinal reperfusion injury by a new inhibitor of sPLA2, COX-1 and COX-2 selective inhibitors, and an LTC4 receptor antagonist Atopic eczema: what's new?Effects of zafirlukast on the function of humanpolymorphonuclear neutrophil leukocytes in asthmatic patients: A prospective, controlled, in vitro study.Cysteinyl Leukotrienes in Eosinophil Biology: Functional Roles and Therapeutic Perspectives in Eosinophilic Disorders The new phosphodiesterase 4 inhibitor roflumilast is efficacious in exercise-induced asthma and leads to suppression of LPS-stimulated TNF-alpha ex vivo.Antitussive effect of the leukotriene receptor antagonist zafirlukast in subjects with cough-variant asthma.A dual CysLT1/2 antagonist attenuates allergen-induced airway responses in subjects with mild allergic asthma.Effects of CYP2C9 genetic polymorphisms on the pharmacokinetics of zafirlukast.Effects of zafirlukast on capsular contracture: controlled study measuring the mammary compliance.Type 2 NADH Dehydrogenase Is the Only Point of Entry for Electrons into the Streptococcus agalactiae Respiratory Chain and Is a Potential Drug Target.Fluconazole but not the CYP3A4 inhibitor, itraconazole, increases zafirlukast plasma concentrations

P2860

Q28263876-9216AF44-D1ED-4909-A861-CFA4FA242943 Q33805187-4F2ACA49-2E4D-4A4B-9E47-450FC46E8621 Q35045639-B284564A-2932-4BC3-86D6-E9D28D4C173B Q36473293-F1685935-D848-44CF-8327-2FB0995F8282 Q37661026-531075C9-4C03-44AC-86FC-F778D1BA6EB2 Q41044958-871B66A3-710A-4F8B-9C93-EBC23418C72D Q43897053-A3CC6CE4-FFD4-4944-BBFF-BFD59B928DC4 Q44048591-7D3E1491-36C3-44F0-802B-70CED8F00A3F Q51485487-BCA3A4DA-C5DB-4CC9-BD0E-6DFE9DD00CDA Q51663926-D07C3A01-703D-42AD-AFB3-3D61B0835455 Q51736672-E8B5F8EA-03BB-4A68-9885-4E4134B35620 Q55518525-3BCB8B90-5D18-4203-8383-20133D962A5B Q57825115-EF0C2DB6-2C23-40E6-BAE4-099BA37A6F21

P2860

Summary of clinical trials with zafirlukast

http://www.wikidata.org/entity/Q42541808

description

1998 nî lūn-bûn

@nan

1998年の論文

@ja

1998年論文

@yue

1998年論文

@zh-hant

1998年論文

@zh-hk

1998年論文

@zh-mo

1998年論文

@zh-tw

1998年论文

@wuu

1998年论文

@zh

1998年论文

@zh-cn

name

Summary of clinical trials with zafirlukast

@en

Summary of clinical trials with zafirlukast

@nl

type

label

Summary of clinical trials with zafirlukast

@en

Summary of clinical trials with zafirlukast

@nl

prefLabel

Summary of clinical trials with zafirlukast

@en

Summary of clinical trials with zafirlukast

@nl

P1433

Q42541808-7034B8A5-61D8-4C86-86BA-E578485A174D

P1476

Q42541808-43010875-DB7F-4BFB-9ABB-BBCAC32A4F0F

P2093

Q42541808-246B4544-EB4F-46B3-A80E-823DBFA3FBAF

P2860

Q42541808-0054DFD9-5F91-47A9-ABD0-D6CE9A51E9B9

Q42541808-4227693E-FFE8-4021-AF4A-15DE4E42749C

Q42541808-5FD97A67-F39F-42C0-9FB2-CB8643E38C67

Q42541808-62BAC7C0-9B11-47D1-A25E-080ECAF5DC17

Q42541808-6342BFF7-AD92-4336-9EB9-3FE3E0D4CE43

Q42541808-738F6503-D741-4C1F-9DB7-5F987BF247EB

Q42541808-778AFAF3-9D84-46E0-A67F-36C875C5438D

Q42541808-8CD00DF8-81FB-4220-8B6C-1BC25A5BE3EE

Q42541808-A170A73E-DA2F-4FA3-980A-9D14E201EA45

Q42541808-D5803191-9C74-46C7-A7A9-7D5EF9B346B0

P304

Q42541808-684FC47D-8415-48A0-9653-2DCB1975AE80

P31

Q42541808-DDD445C5-A274-45D2-BB1D-8636E836FD07

P356

Q42541808-27DA9FD3-0AA7-447D-BBF5-5ED64307D450

P407

Q42541808-14195009-337F-48F5-9DE3-976EB87EF519

P433

Q42541808-296B9D0D-D20F-4DAF-90E8-36AED164FF24

P478

Q42541808-8C4F703D-F615-4B6B-8C62-3FFDE59156E2

P577

Q42541808-7D4E10A2-8189-48B9-8C77-7EF72CB3D3D5

P5875

Q42541808-8C60A989-FE26-44B5-82E5-B4BC0B511D06

P698

Q42541808-33505fbb-45b4-48aa-8dbc-281a48260897

Q42541808-C4266F36-98BE-4643-A643-5E266397DC48

P356

AJRCCM.157.6.MAR6

P1433

American Journal of Respiratory and Critical Care Medicine

P1476

Summary of clinical trials with zafirlukast

@en

P2093

Calhoun WJ

http://www.w3.org/2001/XMLSchema#string

P2860

Role of leukotrienes in exercise-induced asthma. Inhibitory effect of ICI 204219, a potent leukotriene D4 receptor antagonist

Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast.

Inhibition of leukotriene D4-induced bronchoconstriction in normal subjects by the oral LTD4 receptor antagonist ICI 204,219.

Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. ACCOLATE Asthma Trialists Group.

The leukotriene-antagonist ICI-204,219 inhibits the early airway reaction to cumulative bronchial challenge with allergen in atopic asthmatics.

Inhibition of leukotriene D4-induced bronchoconstriction in subjects with asthma: a concentration-effect study of ICI 204,219.

The protective effect of inhaled leukotriene D4 receptor antagonist ICI 204,219 against exercise-induced asthma.

Potent leukotriene D4 receptor antagonist ICI 204,219 given by the inhaled route inhibits the early but not the late phase of allergen-induced bronchoconstriction.

Zafirlukast for symptomatic mild-to-moderate asthma: a 13-week multicenter study. The Zafirlukast Trialists Group.

Effectiveness of the leukotriene receptor antagonist zafirlukast for mild-to-moderate asthma. A randomized, double-blind, placebo-controlled trial.

P304

S238-46

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1164/AJRCCM.157.6.MAR6

http://www.w3.org/2001/XMLSchema#string

P407

P433

6 Pt 1

http://www.w3.org/2001/XMLSchema#string

P478

157

http://www.w3.org/2001/XMLSchema#string

P577

1998-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

13636380

http://www.w3.org/2001/XMLSchema#string

P698

9620946

http://www.w3.org/2001/XMLSchema#string